Bio-Path Stock Price, News & Analysis (NASDAQ:BPTH)

$0.22 0.00 (0.00 %)
(As of 12/12/2017 10:24 AM ET)
Previous Close$0.22
Today's Range$0.20 - $0.22
52-Week Range$0.18 - $1.38
Volume903,500 shs
Average Volume421,240 shs
Market Capitalization$24.78 million
P/E RatioN/A
Dividend YieldN/A
Beta2.92

About Bio-Path (NASDAQ:BPTH)

Bio-Path logoBio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPTH
CUSIPN/A
Phone832-742-1357

Debt

Debt-to-Equity RatioN/A
Current Ratio7.61%
Quick Ratio7.61%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$10,000.00
Price / Sales2,494.58
Cash FlowN/A
Price / CashN/A
Book Value$0.09 per share
Price / Book2.44

Profitability

Trailing EPS($0.07)
Net Income$-6,750,000.00
Net MarginsN/A
Return on Equity-72.98%
Return on Assets-59.29%

Miscellaneous

Employees12
Outstanding Shares113,390,000

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

How were Bio-Path's earnings last quarter?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) issued its earnings results on Thursday, November, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.02). View Bio-Path's Earnings History.

Where is Bio-Path's stock going? Where will Bio-Path's stock price be in 2017?

2 analysts have issued 12-month price targets for Bio-Path's shares. Their predictions range from $1.50 to $2.00. On average, they expect Bio-Path's share price to reach $1.75 in the next year. View Analyst Ratings for Bio-Path.

Who are some of Bio-Path's key competitors?

Who are Bio-Path's key executives?

Bio-Path's management team includes the folowing people:

  • Peter Henry Nielsen, Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer (Age 67)
  • Ulrich W. Mueller Ph.D., Secretary (Age 50)
  • Douglas P. Morris, Director (Age 78)
  • Heath W. Cleaver CPA, Independent Director (Age 43)
  • Mark P Colonnese, Independent Director (Age 61)

How do I buy Bio-Path stock?

Shares of Bio-Path can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path's stock price today?

One share of Bio-Path stock can currently be purchased for approximately $0.22.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $24.78 million and generates $10,000.00 in revenue each year. The company earns $-6,750,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. Bio-Path employs 12 workers across the globe.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 Bellaire Boulevard Suite 210, Bellaire TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]


MarketBeat Community Rating for Bio-Path (BPTH)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  217
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bio-Path (NASDAQ:BPTH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.83$4.00$4.00$4.00
Price Target Upside: 813.98% upside1,233.33% upside1,233.33% upside448.10% upside

Bio-Path (NASDAQ:BPTH) Consensus Price Target History

Price Target History for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ:BPTH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017HC WainwrightReiterated RatingBuy -> Buy$4.50 -> $1.50N/AView Rating Details
4/5/2017Maxim GroupSet Price TargetBuy$2.00HighView Rating Details
8/11/2016Rodman & RenshawSet Price TargetBuy$5.00N/AView Rating Details
(Data available from 12/12/2015 forward)

Earnings

Bio-Path (NASDAQ:BPTH) Earnings History and Estimates Chart

Earnings by Quarter for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ BPTH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.02)($0.02)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.02)($0.03)ViewListenView Earnings Details
5/11/2017Q1 2017($0.02)($0.01)ViewN/AView Earnings Details
3/15/201712/31/2016($0.03)($0.01)$0.01 millionViewListenView Earnings Details
11/9/2016Q316($0.02)($0.02)$2.50 millionViewListenView Earnings Details
8/9/2016Q2($0.02)($0.02)ViewN/AView Earnings Details
5/11/2016Q1($0.01)($0.02)$2.33 millionViewListenView Earnings Details
3/16/2016Q4($0.01)($0.02)$1.46 millionViewN/AView Earnings Details
11/10/2015Q315($0.02)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015Q4 2014$0.01($0.02)ViewN/AView Earnings Details
11/17/2014Q3 2014($0.01)($0.01)ViewN/AView Earnings Details
8/18/2014Q214($0.01)($0.01)ViewN/AView Earnings Details
4/2/2014$0.01$0.01ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Bio-Path (NASDAQ:BPTH) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.09 EPS

Dividends

Dividend History for Bio-Path (NASDAQ:BPTH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bio-Path (NASDAQ BPTH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.20%
Institutional Ownership Percentage: 9.55%
Insider Trades by Quarter for Bio-Path (NASDAQ:BPTH)
Institutional Ownership by Quarter for Bio-Path (NASDAQ:BPTH)

Bio-Path (NASDAQ BPTH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/13/2015Michael J GarrisonDirectorBuy7,343$1.22$8,958.46View SEC Filing  
7/9/2015Michael J GarrisonDirectorBuy8,724$1.17$10,207.08View SEC Filing  
7/8/2015Michael J GarrisonDirectorBuy60,000$1.19$71,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bio-Path (NASDAQ BPTH) News Headlines

Source:
DateHeadline
Financial Comparison: Bio-Path (BPTH) & Brainstorm Cell Therapeutics (BCLI)Financial Comparison: Bio-Path (BPTH) & Brainstorm Cell Therapeutics (BCLI)
www.americanbankingnews.com - November 27 at 5:22 PM
 Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share Analysts Anticipate Bio-Path Holdings, Inc. (BPTH) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - November 20 at 1:28 AM
Bio-Path Holdings, Inc. (BPTH) Given New $1.50 Price Target at Bio-Path Holdings, Inc. (BPTH) Given New $1.50 Price Target at
www.americanbankingnews.com - November 19 at 4:20 PM
Bio-Path Holdings, Inc. (BPTH) Releases Quarterly  Earnings Results, Hits EstimatesBio-Path Holdings, Inc. (BPTH) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - November 10 at 12:51 PM
Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?Bio-Path Holdings Inc (BPTH): How Does It Impact Your Portfolio?
finance.yahoo.com - November 10 at 12:41 PM
Bio-Path Holdings Reports Third Quarter 2017 Financial ResultsBio-Path Holdings Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 5:52 PM
Bio-Path reports 3Q lossBio-Path reports 3Q loss
finance.yahoo.com - November 9 at 5:52 PM
Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts - GlobeNewswire (press release)Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts - GlobeNewswire (press release)
globenewswire.com - November 9 at 12:29 AM
Bio-Path Holdings Highlights Advancements in Preclinical Discovery EffortsBio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts
finance.yahoo.com - November 6 at 5:51 PM
Bio-Path Holdings (BPTH) Announces $4M Registered Direct Offering of Common Stock and WarrantsBio-Path Holdings (BPTH) Announces $4M Registered Direct Offering of Common Stock and Warrants
www.streetinsider.com - November 3 at 5:20 PM
Bio-Path Holdings, Inc. Announces $4 Million Registered Direct OfferingBio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering
finance.yahoo.com - November 3 at 5:20 PM
Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017
finance.yahoo.com - November 3 at 8:25 AM
Bio-Path Holdings, Inc. (BPTH) Scheduled to Post Quarterly Earnings on WednesdayBio-Path Holdings, Inc. (BPTH) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:06 AM
Bio-Path Holdings (BPTH) and Palatin Technologies (PTN) Financial ComparisonBio-Path Holdings (BPTH) and Palatin Technologies (PTN) Financial Comparison
www.americanbankingnews.com - October 30 at 9:28 AM
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH)
finance.yahoo.com - October 23 at 4:37 PM
Is It Time To Buy Bio-Path Holdings Inc (BPTH)?Is It Time To Buy Bio-Path Holdings Inc (BPTH)?
finance.yahoo.com - October 11 at 6:11 PM
Bio-Path Holdings, Inc. (BPTH) Expected to Post Earnings of -$0.02 Per ShareBio-Path Holdings, Inc. (BPTH) Expected to Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - October 11 at 12:20 PM
Bio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowBio-Path (BPTH) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 5:52 PM
Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 11:19 PM
Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare ConferenceBio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference
finance.yahoo.com - September 5 at 6:17 PM
-$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter-$0.02 EPS Expected for Bio-Path Holdings, Inc. (BPTH) This Quarter
www.americanbankingnews.com - September 4 at 4:28 AM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC WainwrightBio-Path Holdings, Inc. (NASDAQ:BPTH) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Releases  Earnings ResultsBio-Path Holdings, Inc. (NASDAQ:BPTH) Releases Earnings Results
www.americanbankingnews.com - August 11 at 2:34 PM
Bio-Path Holdings (BPTH) CEO Peter Nielsen on Q2 2017 Results - Earnings Call TranscriptBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 5:50 PM
Bio-Path reports 2Q lossBio-Path reports 2Q loss
finance.yahoo.com - August 10 at 5:50 PM
Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 - GlobeNewswire (press release)Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 4 at 4:58 PM
Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017
finance.yahoo.com - August 3 at 6:08 PM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Scheduled to Post Quarterly Earnings on TuesdayBio-Path Holdings, Inc. (NASDAQ:BPTH) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:17 AM
Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter PatentBio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent
finance.yahoo.com - July 31 at 4:44 PM
Bio-Path Holdings Receives Notice of Allowance for Key US Composition of Matter Patent - GlobeNewswire (press release)Bio-Path Holdings Receives Notice of Allowance for Key US Composition of Matter Patent - GlobeNewswire (press release)
globenewswire.com - July 20 at 11:21 PM
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Rating Reaffirmed by HC WainwrightBio-Path Holdings, Inc. (NASDAQ:BPTH) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - July 20 at 8:42 AM
Bio-Path Holdings (BPTH) Granted Allowance for Key US Composition of Matter Patent for DNAbilize by USPTO - StreetInsider.comBio-Path Holdings (BPTH) Granted Allowance for Key US Composition of Matter Patent for DNAbilize by USPTO - StreetInsider.com
www.streetinsider.com - July 19 at 5:52 PM
Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors - NasdaqBio-Path Holdings Appoints Mark Colonnese to its Board of Directors - Nasdaq
www.nasdaq.com - July 17 at 5:04 PM
Bio-Path Holdings Appoints Mark Colonnese to its Board of DirectorsBio-Path Holdings Appoints Mark Colonnese to its Board of Directors
finance.yahoo.com - July 17 at 12:23 PM
Stonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) - Baystreet.caStonegate Capital Partners Initiates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) - Baystreet.ca
www.baystreet.ca - June 30 at 4:49 PM
Bio-Path Holdings (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call TranscriptBio-Path Holdings' (BPTH) CEO Peter Nielsen on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 4:36 PM
Bio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - SlideshowBio-Path Holdings (BPTH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 1:49 AM
Bio Path Holdings Inc Earnings Call scheduled for 8:30 am ET todayBio Path Holdings Inc Earnings Call scheduled for 8:30 am ET today
biz.yahoo.com - March 15 at 9:21 PM
Bio-Path Holdings Reports Full Year 2016 Financial ResultsBio-Path Holdings Reports Full Year 2016 Financial Results
us.rd.yahoo.com - March 15 at 4:20 PM
BIO-PATH HOLDINGS INC Files SEC form 10-K, Annual ReportBIO-PATH HOLDINGS INC Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 15 at 4:20 PM
BIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, FiBIO-PATH HOLDINGS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi
us.rd.yahoo.com - March 15 at 4:20 PM
Bio-Path Holdings to Present Data at the 2017 AACR Annual MeetingBio-Path Holdings to Present Data at the 2017 AACR Annual Meeting
us.rd.yahoo.com - March 10 at 4:57 PM
BIO-PATH HOLDINGS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StandBIO-PATH HOLDINGS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
biz.yahoo.com - March 8 at 4:46 PM
Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference - GlobeNewswire (press release)Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 9 at 9:14 PM
BIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD DisclosuBIO-PATH HOLDINGS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosu
biz.yahoo.com - December 16 at 4:21 PM
Bio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016Bio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016
www.streetinsider.com - December 7 at 2:22 AM
Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual MeetingBio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting
us.rd.yahoo.com - December 6 at 4:18 PM
7:01 am Bio-Path reviews BP1001 data as a treatment for chronic myelogenous leukemia at ASH 2016; results demonstrate BP1001 decreased the proliferation of Gleevec (imatinib)-resistant CML cells in a dose-dependent manner7:01 am Bio-Path reviews BP1001 data as a treatment for chronic myelogenous leukemia at ASH 2016; results demonstrate BP1001 decreased the proliferation of Gleevec (imatinib)-resistant CML cells in a dose-dependent manner
us.rd.yahoo.com - December 6 at 4:18 PM
BIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsBIO-PATH HOLDINGS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - December 6 at 4:18 PM
Bio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016 - StreetInsider.comBio-Path Holdings (BPTH) Announces Presentation of BP1001 Data as CML Treatment at ASH 2016 - StreetInsider.com
www.streetinsider.com - December 6 at 12:14 PM

SEC Filings

Bio-Path (NASDAQ:BPTH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bio-Path (NASDAQ:BPTH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bio-Path (NASDAQ BPTH) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.